

CURZA CEO, RYAN DAVIES, SPEAKS AT HARVARD MEDICAL SCHOOL ANTI-INFECTIVE CONFERENCE

BOSTON, Massachusetts—September 7, 2016—Leaders of the biopharmaceutical industry gathered at Harvard Medical School for Anti-Infectives RX, an off-the-record networking conference, to discuss key issues in antibiotic resistance, development, social responsibility, the regulatory landscape and more. Because of Curza's bold strides in the currently unmet medical need of novel antibiotics, Ryan Davies, CEO of Curza spoke at the conference.

Davies moderated the panel addressing the topic "Global Vantage Points: Social Responsibility in R&D," and felt that "it was an honor to speak and serve as a panelist at the Anti-infective Conference."

The coordinators of Anti-Infectives RX have asked Ryan Davies to make a reappearance at their 2017 conference, where he will speak on "Tackling Resistance: The Promise and The Challenge." Davies is happy to return, as he enjoyed hearing from other companies working to combat antimicrobial resistance. He reflected on his experience, remarking that "it was very informative to hear from the different drug development companies, investors, regulators and others. I am pleased to see so many new technologies in the anti-infective space who are all working hard to develop much needed solutions to combat drug-resistant bacteria".

About Curza— Curza is a Utah-based drug development company focused on developing novel therapeutics to combat antibiotic resistant bacteria. With original technology licensed from the University of Utah, Curza is in the early stages of developing two novel classes of antibiotics. Headquartered in Salt Lake City, UT with offices in Cambridge, MA, Curza is privately held and is backed by Clarke Capital Partners and other private investors. Visit www.curza.com for more information.

About Anti-Infectives Rx— An off-the-record, annual networking forum featuring discussion panels from industry CEOs, life science leaders, key academics and investors, Anti-Infectives Rx focuses on issues facing the development of anti-infective, antiviral, and antibacterial therapies.

You can find more information on the Anti-Infectives Rx on Boston Biotech Conferences' website at bbbitech.com.

For media inquiries, please contact: Ryan Davies at rd@curza.com